In a remarkable leap forward in gene editing technology, researchers at The Hong Kong University of Science and Technology (HKUST) have developed the world’s first DNA-guided CRISPR-Cas system capable of programmable RNA recognition and cleavage. This pioneering breakthrough shatters the long-standing dogma in CRISPR biology, which traditionally employed RNA guides to target DNA sequences. By reprogramming the CRISPR system to use DNA as the guiding molecule for RNA cleavage, the innovation promises revolutionary applications spanning therapeutic development, molecular diagnostics, and beyond.
Traditionally, the CRISPR-Cas mechanism functions much like a GPS navigation system: an RNA guide serves as the address directing the Cas enzyme “vehicle” to a specified DNA target. This principle underlies several well-known diagnostic platforms, such as SHERLOCK and DETECTR, which rely on RNA guides to achieve high specificity in DNA targeting. However, the HKUST team inverted this paradigm by engineering a DNA-guided Cas12a system, conferring the unprecedented ability to target and cleave RNA with programmable precision.
The cornerstone of this innovation is the design of a synthetic CRISPR DNA guide (crDNA) that effectively reprograms the Cas12a protein. Unlike the natural system where PAM sequences simultaneously serve as the molecular “activation” signal and informational address, the researchers cleverly decoupled these functions. By constructing a short DNA strand mimicking the PAM-containing duplex, they created a functional deoxyribonucleoprotein complex capable of recognizing any selected RNA molecule for targeted cleavage. This strategic decoupling allowed for a novel mode of RNA recognition previously unseen in CRISPR biology.
To validate this revolutionary concept, the team utilized an integrative approach combining AlphaFold-guided modeling, molecular dynamics simulations, and high-resolution cryo-electron microscopy (cryo-EM). The cryo-EM structural data, collected under the supervision of Prof. Zhai Yuanliang and Dr. Lam Wai-Hei, revealed atomic-level confirmation of the synthetic DNA guide interacting within the Cas12a complex, closely matching computational predictions. This synergy of AI-driven structural prediction and empirical validation underscores the importance of cutting-edge computational tools in accelerating discoveries in gene editing.
One of the defining advantages of substituting RNA guides with DNA lies in the dramatic increase in molecular stability. DNA is inherently chemically more stable than RNA, mitigating the fragile nature of RNA molecules which often necessitate stringent cold-chain requirements for storage and handling. This robustness facilitates more cost-effective, portable, and accessible diagnostic platforms that function reliably at ambient temperatures, making them particularly suitable for deployment in resource-limited settings such as remote clinics and border entry points.
Cost considerations further accentuate the impact of this development. Synthetic DNA guides are significantly less expensive to manufacture due to simpler chemical synthesis protocols and the elimination of cold-chain logistics. While a formal cost-comparison study remains pending, it is widely recognized within biotechnology that RNA molecules require additional chemical protection steps during synthesis, contributing to higher manufacturing costs. The DNA-guided system stands poised to democratize molecular diagnostics by making these tools more affordable and scalable worldwide.
Precision and safety are also markedly enhanced with the DNA-guided CRISPR-Cas12a system. Beyond the enhanced stability, the platform can detect and discriminate single-nucleotide polymorphisms in RNA targets, achieving a level of specificity that RNA interference (RNAi) technologies often fail to match. Moreover, preliminary cellular studies indicate significantly reduced off-target RNA cleavage compared to RNA-targeting CRISPR tools such as Cas13, suggesting a safer profile for future therapeutic applications where minimizing collateral effects is critical.
Importantly, this novel CRISPR configuration transcends the limitations of conventional RNA interference, which primarily targets protein-coding mRNAs. The DNA-guided Cas12a system can be programmed to target a broad spectrum of RNA molecules, including non-coding RNAs such as microRNAs and long non-coding RNAs. These molecules play vital roles in gene regulation and disease pathology, expanding potential applications of this platform to areas previously considered challenging for RNA-targeting technologies.
The team demonstrated the exceptional sensitivity of their system by applying the SLEUTH platform—their name for “Specific Locus Evaluation Utilizing Targeted Hydrolysis”—to clinical samples of SARS-CoV-2. They achieved attomolar-range detection sensitivity for both RNA and DNA targets under diverse conditions, validating the platform’s robustness. This positions SLEUTH as a promising point-of-care diagnostic tool capable of facilitating rapid viral detection without relying on expensive infrastructure or cold-chain preservation.
Beyond diagnostics, the technology heralds significant potential for next-generation antiviral therapies. Given that many pathogenic viruses, including influenza, SARS, and COVID-19, utilize RNA genomes or RNA intermediates during replication, the ability to selectively target and cleave such RNA species offers a platform for innovative antiviral interventions. Such therapies could revolutionize responses to future pandemics, providing precise molecular weapons against viral pathogens.
Looking forward, the research team, including PhD candidate Wu Xiaolong, envisions extending this DNA-guided CRISPR platform’s utility to a broader suite of RNA-based diagnostics and therapeutics. The lab is actively pursuing expansion of the SLEUTH platform to detect additional respiratory viruses and exploring applications in liquid biopsy to identify circulating RNA biomarkers associated with cancers. Additionally, HKUST has filed provisional patents in the United States to secure intellectual property rights for this transformative technology.
This groundbreaking work aligns strategically with HKUST’s recent establishment of a School of Medicine and the institution’s accelerated commitment to translational medicine and RNA-based therapeutic development. By harnessing structural biology, AI-driven design, and bioengineering, the team showcases a cutting-edge approach to gene editing that stands to reshape the biomedical landscape profoundly.
In summary, the introduction of a DNA-guided RNA-targeting CRISPR-Cas12a system represents a paradigm shift in the CRISPR field. It offers a new molecular toolkit blending enhanced stability, precision, safety, and cost-effectiveness with broad applicability across diagnostics, therapeutics, and research. As this technology advances toward clinical translation, it promises to open transformative avenues for precise RNA manipulation in both health and disease.
Subject of Research:
Not applicable
Article Title:
DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage
News Publication Date:
1-May-2026
Web References:
https://www.nature.com/articles/s41587-026-03120-5
References:
10.1038/s41587-026-03120-5
Image Credits:
HKUST
Keywords
CRISPR, Cas12a, DNA-guided CRISPR, RNA targeting, gene editing, molecular diagnostics, antiviral therapy, synthetic guide RNA, SLEUTH platform, cryo-EM, AlphaFold, RNA cleavage
Tags: antiviral therapy developmentCRISPR biology paradigm shiftDNA-guided Cas12a enzyme innovationDNA-guided CRISPR-Cas systemgene editing for therapeutic applicationsHKUST gene editing breakthroughinfectious disease molecular diagnosticsnovel CRISPR diagnostic platformsprogrammable RNA cleavage technologyprogrammable RNA recognition methodsRNA-targeting gene editing toolsynthetic CRISPR DNA guide design
